Myeloperoxidase (MPO) inhibitors (4-MeO-TEMPO [498], ABAH [499, 500], SDG [501,502,503,504,505], KYC [506]) reduce HOCl generation and activate the Nrf2- heme oxygenase-1(HO-1) axis
Nabhani Z, Clark CCT, Goudarzi N, Hariri Far A, Razmpoosh E (2022) The effect of synbiotic supplementation on atherogenic indices, hs-crp, and malondialdehyde, as major cvd-related parameters, in women with gestational diabetes mellitus: a secondary data-analysis of a randomized double-blind, placebo-controlled study
[DOI] [PubMed] [Google Scholar] 93.Vitaic S., Stupnisek M., Drmic D., Bauk L., Kokot A., Klicek R., Vcev A., Luetic K., Seiwerth S., Sikiric P
Oral formulations are mainly discussed for gastrointestinal applications, but research remains limited
The Wegovy pill has only been approved in the US so far
Ipamorelin amplifies each pulse Tesamorelin (Egrifta) Mimics natural GHRH to trigger pituitary GH release Clinical Data CJC-1295/Ipamorelin Phase 2 (CJC-1295), preclinical + Phase 2 (Ipamorelin) Tesamorelin (Egrifta) Two Phase 3 RCTs, 816 patients Approved Indication CJC-1295/Ipamorelin None (compounded) Tesamorelin (Egrifta) HIV-associated lipodystrophy Availability CJC-1295/Ipamorelin Compounding pharmacy with prescription Tesamorelin (Egrifta) Compounding pharmacy with prescription (also as branded Egrifta) PeRx Offers Both PeRx prescribes both CJC-1295/Ipamorelin and Tesamorelin